Apogee Therapeutics (APGE) CEO discloses planned insider stock sales on December 10

Rhea-AI Filing Summary

Apogee Therapeutics, Inc. Chief Executive Officer and director Michael Henderson reported insider sales of common stock. On December 10, 2025, he sold a total of 20,000 shares of Apogee common stock in three transactions at weighted-average prices of $74.88, $75.79, and $76.58 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025.

Following these sales, Henderson beneficially owns 1,212,987 shares of Apogee common stock directly. Some of the reported prices represent weighted averages for multiple trades executed within price ranges from $74.30 to $75.29 and from $75.30 to $76.28 per share, and he has agreed to provide detailed trade information to Apogee, any shareholder, or the SEC upon request.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENDERSON MICHAEL THOMAS

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2025		S(1)		9,435	D	$74.88(2)	1,223,552	D
Common Stock	12/10/2025		S(1)		10,005	D	$75.79(3)	1,213,547	D
Common Stock	12/10/2025		S(1)		560	D	$76.58	1,212,987	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.30 to $75.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.30 to $76.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Matthew Batters, as attorney-in-fact for Michael Henderson	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Apogee Therapeutics (APGE) disclose for its CEO?

Apogee Therapeutics reported that Chief Executive Officer and director Michael Henderson sold common stock and disclosed the activity in a Form 4 insider transaction report.

How many APGE shares did Michael Henderson sell on December 10, 2025?

On December 10, 2025, Michael Henderson sold a total of 20,000 Apogee Therapeutics common shares in three separate transactions of 9,435, 10,005, and 560 shares.

At what prices were Michael Henderson’s APGE shares sold?

The reported weighted-average sale prices were $74.88, $75.79, and $76.58 per share, with underlying trades executed in ranges from $74.30 to $75.29 and from $75.30 to $76.28 per share.

How many Apogee Therapeutics (APGE) shares does the CEO hold after these sales?

After the reported transactions, Michael Henderson beneficially owns 1,212,987 shares of Apogee Therapeutics common stock directly.

Were the CEO’s APGE stock sales made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were executed pursuant to a Rule 10b5-1 trading plan that Michael Henderson adopted on August 13, 2025.

Did this Apogee Therapeutics Form 4 report any derivative securities activity?

The Form 4 includes a table for derivative securities, but no derivative transactions or holdings are reported in that section for this filing.